T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia

Blood

Volumn 107, Issue 10, 2006, Pages 3983-3991

  Solomou, Elena E ^a,b   Keyvanfar, Keyvan ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CALPHOSTIN; GAMMA INTERFERON; ROTTLERIN; TRANSCRIPTION FACTOR T BET;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG INHIBITION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SCHOOL CHILD; T LYMPHOCYTE; UPREGULATION;

EID: 33646546357     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-10-4201     Document Type: Article

References (55)

1. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534-546.
2. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365-1372.
3. Young NS. Introduction: acquired aplastic anemia. Semin Hematol. 2000;37:2.
4. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol. 2000;37:3-14.
5. Young NS. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med. 1997;126:166-168.
6. Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol. 2002;75:129-140.
7. Young NS. Gamma interferon and aplastic anemia. Blood. 1987;70:337-339.
8. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985;82:188-192.
9. Giannakoulas NC, Karakantza M, Theodorou GL, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol. 2004;124:97-105.
10. Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100:1185-1191.
11. Zoumbos NC, Djeu JY, Young NS. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol. 1984;133:769-774.
12. Young NS, Leonard E, Platanias L. Lymphocytes and lymphokines in aplastic anemia: pathogenic role and implications for pathogenesis. Blood Cells. 1987;13:87-100.
13. Risitano AM, Maciejewski JP, Green S, et al. Invivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364:355-364.
14. Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985;312:257-265.
15. Bloom ML, Wolk AG, Simon-Stoos KL, et al. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol. 2004;32:1163-1172.
16. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655-669.
17. Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 2002;295:338-342.
18. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today. 2000;21:479-483.
19. Penix LA, Sweetser MT, Weaver WM, et al. The proximal regulatory element of the interferon-gamma promoter mediates selective expression in T cells. J Biol Chem. 1996;271:31964-31972.
20. Sweetser MT, Hoey T, Sun YL, et al. The roles of nuclear factor of activated T cells and ying-yang 1 in activation-induced expression of the interferon-gamma promoter in T cells. J Biol Chem. 1998;273:34775-34783.
21. Tong Y, Aune T, Boothby M. T-bet antagonizes mSin3a recruitment and transactivates a fully methylated IFN-gamma promoter via a conserved T-box half-site. Proc Natl Acad Sci U S A. 2005;102:2034-2039.
22. Finotto S, Glimcher L. T cell directives for transcriptional regulation in asthma. Springer Semin Immunopathol. 2004;25:281-294.
23. Hatton RD, Weaver CT. Immunology: T-bet or not T-bet. Science. 2003;302:993-994.
24. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 2002;295:336-338.
25. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol. 2002;3:549-557.
26. Mullen AC, Hutchins AS, High FA, et al. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol. 2002;3:652-658.
27. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol. 2002;20:761-794.
28. Altman A, Isakov N, Baier G. Protein kinase Ctheta: a new essential superstar on the T-cell stage. Immunol Today. 2000;21:567-573.
29. Carter CA, Kane CJ. Therapeutic potential of natural compounds that regulate the activity of protein kinase C. Curr Med Chem. 2004;11:2883-2902.
30. Solomou EE, Juang YT, Tsokos GC. Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the -180 site of the IL-2 promoter in normal human T lymphocytes. J Immunol. 2001;166:5665-5674.
31. Coudronniere N, Villalba M, Englund N, Altman A. NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Natl Acad Sci U S A. 2000;97:3394-3399.
32. Tan Y, Rouse J, Zhang A, et al. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 1996;15:4629-4642.
33. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen-and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426-4441.
34. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol. 2001;166:4216-4222.
35. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science. 2005;307:430-433.
36. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-156.
37. Wange RL, Samelson LE. Complex complexes: signaling at the TCR. Immunity. 1996;5:197-205.
38. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol. 2000;18:451-494.
39. Monks CR, Kupfer H, Tamir I, Barlow A, Kupfer A. Selective modulation of protein kinase C-theta during T-cell activation. Nature. 1997;385:83-86.
40. Meller N, Elitzur Y, Isakov N. Protein kinase C-theta (PKCtheta) distribution analysis in hematopoietic cells: proliferating T cells exhibit high proportions of PKCtheta in the particulate fraction. Cell Immunol. 1999;193:185-193.
41. Bacigalupo A, Podesta M, Mingari MC, et al. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol. 1980;125:1449-1453.
42. Weigmann B, Neurath MF. T-bet as a possible therapeutic target in autoimmune disease. Expert Opin Ther Targets. 2002;6:619-622.
43. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002;195:1129-1143.
44. Li B, Yang P, Zhou H, et al. T-bet expression is upregulated in active Behcet's disease. Br J Ophthalmol. 2003;87:1264-1267.
45. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A. 2002;99:5545-5550.
46. Sasaki Y, Ihara K, Matsuura N, et al. Identification of a novel type 1 diabetes susceptibility gene, T-bet. Hum Genet. 2004;115:177-184.
47. Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol. 2005;5:284-295.
48. Lucas JA, Miller AT, Atherly LO, Berg LJ. The role of Tec family kinases in T cell development and function. Immunol Rev. 2003;191:119-138.
49. Schaeffer EM, Debnath J, Yap G, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science. 1999;284:638-641.
50. Dombroski D, Houghtling RA, Labno CM, et al. Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton. J Immunol. 2005;174:1385-1392.
51. Labno CM, Lewis CM, You D, et al. Itk functions to control actin polymerization at the immune synapse through localized activation of Cdc42 and WASP. Curr Biol. 2003;13:1619-1624.
52. Srivastava KK, Batra S, Sassano A, et al. Engagement of protein kinase C-theta in interferon signaling in T-cells. J Biol Chem. 2004;279:29911-29920.
53. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005;5:521-531.
54. Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J AmAcad Dermatol. 2005;53:291-302.
55. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.